利拉鲁肽对肥胖2型糖尿病合并非酒精性脂肪肝患者的肝脏脂肪沉积的影响研究  

Effects of liraglutide on hepatic fat deposition in obese patients with type 2 diabets and non-alcoholic fatty liver disease

作　　者：杨帆[1,2] 李钶[3] 蒋晓岚[1] 李健[1] 王翔[1] 曾庆华[1] 余婷婷[4] 

机构地区：[1]四川省医学科学院/四川省人民医院全科医学中心,成都610072 [2]四川大学华西医院金卡医院,成都610072 [3]重庆医科大学附属第二医院内分泌科,400010 [4]四川大学华西保健医院内分泌及代谢科,成都610043

出　　处：《重庆医学》2016年第25期3493-3495,共3页Chongqing medicine

基　　金：四川省卫生厅科研基金项目(120116)

摘　　要：目的探讨利拉鲁肽对肥胖2型糖尿病合并非酒精性脂肪肝患者的肝脏脂肪沉积的影响。方法 71例经二甲双胍单药治疗血糖控制不佳的肥胖2型糖尿病合并非酒精性脂肪肝患者使用利拉鲁肽治疗6个月,观察治疗后血糖、血脂、血压相关指标的变化,采用瞬时弹性成像技术评价肝脏脂肪沉积情况。结果加用利拉鲁肽治疗后患者的空腹血糖(FPG)、餐后2h血糖(2hPBG)、糖化血红蛋白(HbA1c)、体质量指数(BMI)和胰岛素抵抗指数(HOMA-IR)较治疗前降低(P<0.01);脂肪受控衰减参数及肝脏硬度也明显降低(P<0.01)。结论利拉鲁肽治疗肥胖2型糖尿病合并非酒精性脂肪肝患者能降低血糖、血脂和血压水平,还可以改善患者的肝脏脂肪沉积。Objective To investigate the efftects of liraglutide on hepatic fat deposition in obese patients with type 2 diabets and non-alcoholic fatty liver disease. Methods Totally 71 obese＇patients with type 2 diabetes and non-alcoholic fatty liver disease which have poor glycemic control undergoing single antidiabetic-drug treatment with metformin were participated in the study. The patients were treated with liraglutide for 6 month. FBG, 2hPBG, HbA1C, BMI, HOMA-IR, CAP and LSM were measured, transient elastic imaging technique was used to Evaluate the hepatic fat deposition. Results After liraglutide therapy,FBG,2hPBG, HbA1C, BMI,HOMA-IR were significantly decreased （P〈0.01） ;CAP and LSM were also decreased （P〈0.01）. Conclusion Treatment with liraglutide on top of ongoing rnetformin therapy in obese patients with type 2 diabetes and non-alcoholic fatty liver significantly reduces the hepatic fat deposition.

关 键 词：糖尿病 2型 利拉鲁肽 非酒精性脂肪肝 肥胖 肝脏脂肪沉积 

分 类 号：R587.1[医药卫生—内分泌] R589.2[医药卫生—内科学] R575.5[医药卫生—临床医学]